全球呼吸道病毒活动：每周更新N°570

GLOBAL INFLUENZA SURVEILLANCE AND RESPONSE SYSTEM (GISRS) Co-circulationInfluenzaSARS-CoV-2RSVSeverity assessment SUMMARY Globally, influenza positivity was around 10% in week 11 2026. SARS-CoV-2 activity remained low overall. Influenza predominated and positivity wasaround 10% in the northern hemisphere temperate and subtropical areas and in tropical areas. In the southern hemisphere temperate and subtropical areas,influenza and SARS-CoV-2 positivity were both low. [Figures 1a, 1b, 1c and 1d] Globally, RSV positivity remained stable and low. qInfluenza Globally, influenza detections continued to decline in week 11. Influenza B viruses were predominant among influenza detections. [Figure 2] In the northern hemisphere, influenza percent positivity was elevated (>10%) in countries in North America, Western, Southern and South-East Asia.Percent positivity was over 30% in countries in Central America and the Caribbean, Western Africa, Europe and Eastern Asia. Increases in activitywere observed in a few countries in Central America and the Caribbean and in single countries in Western Africa, Eastern Europe and Western Asia.[Figures 3 and 4] In the southern hemisphere, influenza activity remained low overall although elevated positivity (>10%) was reported in single countries in TemperateSouth America, Southern and Eastern Africa and South-East Asia. Percent positivity was over 30% in one country in Tropical South America. Asmall increase in activity was observed in a single country in Southern Africa. [Figures 3 and 4] In the zones with elevated positivity, influenza A(H3N2) was predominant in Central America and the Caribbean, Tropical and Temperate SouthAmerica, Eastern Europe, Western and Southern Asia. Influenza A(H3N2) and B were codominant in North America and South-East Asia andinfluenza A(H1N1)pdm09 and A(H3N2) were codominant in South West and Northern Europe. Influenza B was dominant in Western Africa andEastern Asia and influenza A(H1N1)pmd09 was dominant in Southern Africa. [Figures 5 and 6] qSARS-CoV-2Globally, SARS-CoV-2 positivity remained stable and low, with a single country reporting a small increase in activity and positivity above 10% in Oceania. [Figures 7 and 8] qRespiratory Syncytial Virus (RSV)Globally, RSV positivity remained stable and low, with a few countries reporting elevated positivity (>10%) in Eastern Africa, Europe and Western Asia. Percent positivity was over 30% in one country in Northern Africa. A small increase in activity was reported in a single country in South WestEurope. [Figures 9 and 10] RSV and influenza activity were both elevated in countries in Europe. qSeverity assessmentThe severity assessments here are reported from countries, areas and territories. Assessments for transmissibility can be reported based on syndromic parameters and/or influenza-specific parameters. In the northern hemisphere temperate and subtropical areas, influenza-specific transmissibilitywas reported as moderate (1); transmissibility using syndromic data was reported as below seasonal threshold (23), low (2) and moderate (2).Influenza-specific transmissibility was reported as below seasonal threshold in a single country in the southern hemisphere temperate and subtropicalareas. [Figures 11 and 12] Co-circulation of influenza and SARS-CoV-2 1c) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in tropical areas 1d) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in southern hemispheretemperate and subtropical areas 1b) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in northern hemispheretemperate and subtropical areas Influenza 3) Proportions of specimens that tested positive forinfluenza (year-week:2026-11) 4) Change in proportions of specimens that testedpositive for influenza (year-week:2026-11) 6) Weekly distribution of influenza virus types andsubtypes by geographic zone (last 12 months) 5) Proportions of influenza virus types and subtypes byinfluenza transmission zones (year-week:2026-11) SARS-CoV-2 7) Proportions of specimens that tested positive forSARS-CoV-2 (year-week:2026-11) 8) Change in proportions of specimens that testedpositive for SARS-CoV-2 (year-week:2026-11) Respiratory syncytial virus 9) Proportions of specimens that tested positive for RSV(year-week:2026-11) 10) Change in proportions of specimens that testedpositive for RSV (year-week:2026-11) Severity assessment 12) Syndromic transmissibility (year-week:2026-11) 11) Influenza specific transmissibility (year-week:2026-11) 13) Number of countries, areas or territories reporting to FluNet (from year-week2026-07to year-week2026-11) Additional information Data and methodsThe data presented in this report originates from virologic surveillance conducted by countries, areas, and territories (CATs) and submitted to WHO FluNet through participation or collaboration with the Globa